Zimtu Capital Corp. Invests in Xander Resources Inc.
VANCOUVER, BC / / March 26, 2025 / Zimtu Capital Corp. (TSXv:ZC)(FSE:ZCT1) ("Zimtu" or the "Company") announces that its has acquired 1,315,790 units (the "Units") of Xander Resources Inc. ("Xander") at a price of $0.19 per Unit pursuant to a private placement offering undertaken by Xander (the "Offering"). The Units are comprised of 1,315,790 common shares and 1,315,790 share purchase warrants. Each warrant entitles the holder to purchase one additional share at a price of $0.25 per share within three (3) years from the date of closing.
Prior to the closing of the Offering, Zimtu did not own or control any securities of Xander. Following closing of the Offering, Zimtu holds 1,315,790 common shares in the capital of Xander and 1,315,790, representing 16.6% of the issued and outstanding common shares of Xander, on an undiluted basis, and 28.5% of the issued and outstanding common shares of Xander on a partially diluted basis.
Zimtu acquired the Units for investment purposes only, and depending on market and other conditions, may from time to time in the future increase or decrease its ownership, control or direction over securities of Xander, through market transactions, private agreements or otherwise.
This news release is issued pursuant to the requirements set forth in National Instrument 62-103 - The Early Warning System and Related Take-Over Bid and Insider Reporting Issues and National Instrument 62-104 - Take-Over Bids and Issuer Bids. Zimtu will be filing an early warning report with respect to the acquisition of the Units containing additional information under Xander's SEDAR+ profile at www.sedarplus.ca.
About Zimtu Capital Corp.Zimtu Capital Corp. is a public investment issuer that aspires to achieve long-term capital appreciation for its shareholders. Zimtu Capital companies may operate in the fields of mineral exploration, mining, technology, life sciences or investment. The Company trades on the TSX Venture Exchange under the symbol "ZC" and Frankfurt under symbol "ZCT1". For more information, please visit https://www.zimtu.com.
On Behalf of the Board of DirectorsZIMTU CAPITAL CORP.
"Sean Charland"President & DirectorTel: 604.681.1568
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements, which include any information that addresses activities, events or developments that the Company believes, expects or anticipates will or may occur in the future. Forward-looking statements in this press release include statements that the Company may from time to time increase or decrease its ownership, control or direction over securities of Xander, depending upon market or other conditions and statements; that the Company will file an early warning report respecting the acquisition of the Units; and that the Company aspires to achieve long-term capital appreciation for its shareholders. These statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from those expressed, implied by or projected in the forward-looking information or statements. Important factors that could cause actual results to differ from these forward-looking statements include, but are not limited to: risks associated with the business of the Company or the businesses of the companies that the Company has invested in, including, without limitation, the natural resource exploration industry; changes in commodity prices as the Company has investments in natural resource exploration issuers; changes in interest and currency exchange rates; geopolitical risk and social unrest; changes in general economic conditions or conditions in the financial markets; and economic, competitive, governmental, environmental and technological factors which may affect the Company's operations, investments, markets, products and share price. Except as required by law, the Company does not intend to revise or update these forward-looking statements after the date of this document or to revise them to reflect the occurrence of future unanticipated events.
SOURCE: Zimtu Capital Corp.
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Court Grants Final Order to Lumina Gold Approving Arrangement with CMOC
VANCOUVER, BC, June 19, 2025 /CNW/ - Lumina Gold Corp. (TSXV: LUM) (OTCQB: LMGDF) (the "Company" or "Lumina") is pleased to announce that the Supreme Court of British Columbia (the "Court") has issued a final order approving the previously announced plan of arrangement (the "Arrangement") pursuant to which 1536188 B.C. Ltd. ("Acquireco"), a wholly-owned subsidiary of CMOC Singapore Pte. Ltd. (the "Purchaser") will acquire all of the issued and outstanding common shares of Lumina, as previously jointly announced on April 21, 2025. Subject to the satisfaction or waiver of the remaining conditions to closing contained in the arrangement agreement entered into among the Company, Acquireco and the Purchaser dated April 21, 2025 (the "Arrangement Agreement"), the Arrangement is expected to close in late June 2025. The Arrangement is subject to the final approval of the TSX Venture Exchange. About Lumina Gold Lumina Gold Corp. (TSXV: LUM) is a Vancouver, Canada based exploration company focused on the Cangrejos project located in El Oro Province, southwest Ecuador. In 2023, the Company completed a Pre-Feasibility Study for the Project, which is the largest primary gold deposit in Ecuador. Lumina has an experienced management team with a successful track record of advancing and monetizing exploration projects. Follow us on: Twitter, LinkedIn or Facebook. Further details are available on the Company's website at To receive future news releases please sign up at LUMINA GOLD CORP. Signed: "Marshall Koval" Marshall Koval, President & CEO, Director Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. Cautionary Note Regarding Forward-Looking Information Certain statements and information herein, including all statements that are not historical facts, contain forward-looking statements and forward-looking information within the meaning of applicable securities laws. Such forward-looking statements or information include but are not limited to statements or information with respect to: the terms and conditions of the Arrangement; receipt of final regulatory approval; the closing and expected timing of closing of the Arrangement. Often, but not always, forward-looking statements or information can be identified by the use of words such as "will" or "projected" or variations of those words or statements that certain actions, events or results "will", "could", "are proposed to", "are planned to", "are expected to" or "are anticipated to" be taken, occur or be achieved. With respect to forward-looking statements and information contained herein, the Company has made numerous assumptions including among other things, assumptions about general business and economic conditions, metals prices, the timely receipt of necessary approvals, the Company's ability to comply with the terms and conditions of the Arrangement Agreement, no unplanned delays or interruptions, and expected Ecuador national, provincial and local government policies. The foregoing list of assumptions is not exhaustive. Although management of the Company believes that the assumptions made and the expectations represented by such statements or information are reasonable, there can be no assurance that a forward-looking statement or information herein will prove to be accurate. Forward-looking statements and information by their nature are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements or information. These factors include, but are not limited to: risks associated with the business of the Company; business and economic conditions in the mining industry generally; the supply and demand for labour and other project inputs; changes in commodity prices; changes in interest and currency exchange rates; risks relating to inaccurate geological and engineering assumptions (including with respect to the tonnage, grade and recoverability of reserves and resources); risks relating to unanticipated operational difficulties (including failure of equipment or processes to operate in accordance with specifications or expectations, cost escalation, unavailability of materials and equipment, government action or delays in the receipt of government approvals, industrial disturbances or other job action, and unanticipated events related to health, safety and environmental matters); risks relating to adverse weather conditions; political risk and social unrest; changes in general economic conditions or conditions in the financial markets; and other risk factors as detailed from time to time in the Company's continuous disclosure documents filed with Canadian securities administrators. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company does not undertake to update any forward-looking information, except in accordance with applicable securities laws. View original content to download multimedia: SOURCE Lumina Gold Corp. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
11 hours ago
- Business Wire
RDDT Investors Have Opportunity to Lead Reddit, Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Reddit, Inc. ('Reddit' or 'the Company') (NYSE: RDDT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between October 29, 2024 and May 20, 2025, inclusive (the 'Class Period'), are encouraged to contact the firm before August 18, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Reddit's traffic was negatively impacted by changes to Google's search algorithm and features like AI Overview. The Company's traffic was impacted in materially different ways than it had been by prior Google changes. The Company was aware that Google users added 'Reddit' to their search hoping to get a answer to their question without actually visiting Reddit. The Company failed to overcome the challenges caused by Google in the short term. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Reddit, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Wire
12 hours ago
- Business Wire
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
LYON, France--(BUSINESS WIRE)--Regulatory News: Following the submission of the Marketing Authorization Application to the EMA for our lead asset, we are excited to advance Xervyteg® toward commercialization — a potential world first for a microbiota therapeutic in oncology. Share MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, today provides a business update and highlights its key milestones expected for the second half of 2025. 'Following the submission of the Marketing Authorization Application to the EMA for our lead asset, Xervyteg ®, earlier this month, we are excited to advance Xervyteg ® toward commercialization — a potential world first for a microbiota therapeutic in oncology — and are now fully focused on progressing registration activities across Europe', said Hervé Affagard, CEO and co-founder of MaaT Pharma. 'This marks a major step in confirming our commitment to address high unmet medical needs and, importantly, it serves as a stepping stone toward international expansion, as we aim to bring our therapies to patients worldwide" Pipeline highlights In Hemato-Oncology Acute Graft-versus-Host Disease (aGvHD) – Xervyteg ® (MaaT013) In January 2025, the Company announced positive topline results from the pivotal Phase 3 ARES Study evaluating Xervyteg ® (MaaT013) in aGvHD. The study met its primary endpoint with a significant gastrointestinal overall response rate at Day 28 of 62% and demonstrates the unprecedented efficacy of Xervyteg ® as third-line treatment of aGvHD with gastrointestinal involvement (GI-aGvHD) consistent with communicated Early Access Program results. On June 02, 2025, the Company announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for its lead drug candidate MaaT013, under the registered brand name of Xervyteg ®. If approved, the Marketing Authorization would establish Xervyteg ® as the first microbiota therapeutic approved by the EMA, the first one in hemato-oncology worldwide and the first approved therapy in third-line GI-aGvHD. On June 13, 2025, the Company presented positive updated data in Early Access Program for 173 patients at the 2025 annual EHA Congress supporting the high efficacy and good safety profile of Xervyteg ®. This dataset confirms the breakthrough potential of Xervyteg ® for aGvHD patients with limited treatment options. Final results from the pivotal ARES study, including 12-month overall survival data, are expected before the end of 2025 and will be incorporated into the filing dossier. The potential marketing authorization could be delivered around mid-2026, enabling the start of the commercialization of Xervyteg ® in Europe. MaaT Pharma is advancing discussions with potential partners to accelerate the commercialization plan across Europe. MaaT Pharma primarily focuses on the commercialization of its most advanced asset with the completion of regulatory steps in Europe, and dedicated preparation activities for the European launch of Xervyteg ®. In parallel, the Company continues discussions with the FDA to optimize a dedicated pivotal study in the U.S., with the objective of enabling the earliest possible access to Xervyteg ® for U.S. patients. Such a study could be initiated in 2026 (instead of Q4 2025), subject to regulatory confirmation as MaaT Pharma continues watching the evolving regulatory policies and process in the United States. The Company continues the ongoing Early Access Program in the United States, initiated in December 2024. Allogenic Hematopoietic Stem Cell Transplant (allo-HSCT) - MaaT033 Over the past 12 months, three DSMB safety assessments were conducted for MaaT033 in the Phase 2b PHOEBUS randomized trial designed to be pivotal: two routine evaluations and one interim analysis focused on excess mortality. All confirmed a favorable safety profile and recommended continuation of the trial without modifications. The last patient enrollment in the trial is anticipated for mid-2026 while the 1-year OS results are expected in H2 2027. In Immuno-Oncology Xervyteg ® and MaaT033 – Proof-of-Concept trials using the MET-N platform (donor derived conducted as Investigator-Sponsored Trials (ISTs). In March 2024, the Company completed patient recruitment for the Phase 2a randomized clinical trial (NCT04988841) (PICASSO) sponsored by AP-HP in Paris and in collaboration with INRAE and Institut Gustave Roussy, evaluating Xervyteg ® in combination with immune checkpoint inhibitors (ICI), ipilimumab (Yervoy ®) and nivolumab (Opdivo ®), in metastatic melanoma patients. The Company provided its Xervyteg ® drug candidate and placebo and contributes to the microbiome profiling of patients using its proprietary gutPrint ® AI research engine, while the trial investigator-sponsor handled recruitment, treatment and is overseeing data collection and analysis. Data readout is expected in H2 2025 as previously announced. In May 2024, the Company announced its participation in the IMMUNOLIFE 'RHU' (university hospital trial) program, a consortium including academic partners, such as Institut Gustave Roussy (IGR), a world-renowned center in the field of cancer treatment, and biotech companies. MaaT033 will be tested as a concomitant treatment to cemiplimab (Regeneron), an anti-PD1 therapy, to assess the potential increase in response rate in patients having received antibiotics. This investigator-sponsored, randomized, multicenter Phase 2 trial will evaluate MaaT033 in patients with advanced non-small cell lung cancer (NSCLC), with MaaT Pharma supplying the investigational product. The trial is expected by the sponsor to start mid-2025. MaaT034 – Next-generation drug candidates with co-cultured technology (MET-C platform) In April 2025, the Company presented new preclinical data for MaaT034, its next generation product, showing compelling anti-tumor efficacy results in germ-free mice at the American Association for Cancer Research (AACR) Annual Meeting 2025. Key results included: Metagenomic analysis shows that MaaT034 reproduces the microbial functions of Xervyteg ® MaaT034 improves DC-mediated T cell activation and potentiates anti-tumor effects mediated by anti-PD-1 checkpoint blockade in vitro. 70% of MaaT034 microbial species engraft in mice, ensuring an enduring presence of beneficial bacteria in the gut environment. MaaT034 increases the production of key microbial-derived metabolites such as short-chain fatty acids in germ-free mice. This translates into an improved gastrointestinal physiology as evidenced by gut mucosal restoration. MaaT034 optimizes anti-PD1 mediated activity in tumor-bearing, germ-free mice. While anti-PD1 alone reduced tumor growth by 10%, the combination of anti-PD1 and MaaT034 resulted in a 83.7% tumor growth reduction (compared to a 24.2% reduction when using a single strain of Akkermansia muciniphila bacteria). In Neurodegenerative Diseases In May 2025, MaaT Pharma announced positive final Phase 1b results for MaaT033 in Amyotrophic Lateral Sclerosis (ALS), showing a favorable safety and tolerability profile supported by biomarker and microbiome analyses. Moving forward, the Company is seeking a partner to further advance clinical evaluation in ALS. As a reminder, the Company's Annual General Meeting will take place on Friday, June 20, 2025, at 9:30am CET at the Company's headquarter in France located at 70 avenue Tony Garnier, 69007 Lyon and will also be broadcasted live. A presentation by the management team on recent developments and perspectives will take place from 9:00 to 9:30 a.m. CET, prior to the General Meeting. For more information, please visit the investors section on the Company's website. --- About MaaT Pharma MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France. As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021. Forward-looking Statements All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
